Rovadicitinib
- Generic Name
- Rovadicitinib
Graves' Disease and Graft-versus-Host Disease: Pipeline Therapeutics Update
• Several companies are actively developing novel therapies for Graves' Disease, targeting mechanisms like IGF-1R and FcRn.
• Clinical trials are underway for Batoclimab (Phase III), VRDN-001 (Phase III), and Linsitinib (Phase II/III) to address Graves' Disease.
• The Graft-versus-Host Disease pipeline includes over 65 drugs in development, with companies like MaaT Pharma and Syndax Pharmaceutical leading the way.
• Therapies like MaaT013 and axatilimab are in advanced stages of clinical trials, offering potential new treatments for Graft-versus-Host Disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath